Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

4 Entertainment Stocks That Could Bounce Back Post-Quarantine

By Thomas Niel, InvestorPlace Contributor

Consider these four entertainment names top stocks to buy in January: Cinemark (NYSE:CNK) Cedar Fair LP (NYSE:FUN) Madison Square Garden Sports (NYSE:MSGS) Dave & Buster's Entertainment (NASDAQ:PLAY)

It’s Still Too Early to Buy the Palantir Stock Pullback

By Thomas Niel, InvestorPlace Contributor

Don't buy the dip in Palantir stock. PLTR could quickly head below $20 per share in the coming months due to multiple factors.

Up 146% Since its IPO, Take Your Time with Airbnb Stock

By Thomas Niel, InvestorPlace Contributor

So, what's the call? Wait things out with Airbnb stock. At the right price, it may be a screaming buy. But, at today's prices? Not so much.

As Lidar Fever Hits Wall Street, Be Careful With Luminar Stock

By Thomas Niel, InvestorPlace Contributor

The future remains bright for lidar play LAZR stock, but watch out as shares currently change hands at unsustainable levels.

As Vaccine Excitement Fades, Buy the Pullback in Pfizer

By Thomas Niel, InvestorPlace Contributor

With its solid dividend yield and reasonable valuation, there's more to like about PFE stock than just Pfizer's pandemic catalyst.

Load More